Document Detail

Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease.
MedLine Citation:
PMID:  18307413     Owner:  NLM     Status:  MEDLINE    
The aim of the present study was to assess circulating levels of VEGF (vascular endothelial growth factor), a biomarker with prognostic significance in cardiovascular disease, and markers of systemic inflammation in patients with stable and exacerbated COPD (chronic obstructive pulmonary disease). Lung function parameters, arterial blood gas analysis and circulating levels of VEGF, IL-6 (interleukin-6), TNF-alpha (tumour necrosis factor-alpha), CRP (C-reactive protein), fibrinogen and the peripheral blood neutrophil cell count were assessed in 30 patients on admission to the hospital for acute exacerbation of COPD, in 30 age-, gender- and BMI (body mass index)-matched patients with stable COPD, and 30 matched controls with normal lung function. Patients with acute exacerbated COPD had higher circulating concentrations of VEGF (P<0.001), IL-6 (P<0.05) and CRP (P<0.01) and an increased blood neutrophil cell count (P<0.05) compared with patients with stable COPD and healthy controls. VEGF levels in exacerbated COPD correlated with systemic inflammatory markers, such as CRP (r=0.61, P<0.005), IL-6 (r=0.46; P<0.01) and fibrinogen (r=0.39, P<0.05). In patients with stable COPD, there was a significant relationship between circulating VEGF levels and the percentage of the predicted FEV(1) (forced expiratory volume in 1 s) (r=0.47, P<0.01). Recovery from the exacerbation resulted in a significant decrease in both circulating VEGF levels and markers of systemic inflammation. In conclusion, circulating levels of VEGF and markers of systemic inflammation are up-regulated in patients with acute exacerbated COPD and decrease after recovery from the exacerbation.
Arschang Valipour; Martin Schreder; Michael Wolzt; Sleman Saliba; Sonja Kapiotis; Philipp Eickhoff; Otto Chris Burghuber
Related Documents :
14644863 - Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study.
12092633 - Homocysteine and c-reactive protein levels in haemodialysis patients.
19478643 - Measurement of change in estimated glomerular filtration rate in patients with renal in...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical science (London, England : 1979)     Volume:  115     ISSN:  1470-8736     ISO Abbreviation:  Clin. Sci.     Publication Date:  2008 Oct 
Date Detail:
Created Date:  2008-08-28     Completed Date:  2008-10-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7905731     Medline TA:  Clin Sci (Lond)     Country:  England    
Other Details:
Languages:  eng     Pagination:  225-32     Citation Subset:  IM    
Department of Respiratory and Critical Care Medicine, Ludwig Boltzmann Institute for Chronic Obstructive Pulmonary Disease, Otto-Wagner-Hospital, Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Biological Markers / blood
C-Reactive Protein / metabolism
Cytokines / blood
Forced Expiratory Volume
Inflammation Mediators / blood*
Middle Aged
Oxygen / blood
Partial Pressure
Pulmonary Disease, Chronic Obstructive / blood*,  physiopathology
Vascular Endothelial Growth Factor A / blood*
Reg. No./Substance:
0/Biological Markers; 0/Cytokines; 0/Inflammation Mediators; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 7782-44-7/Oxygen; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation ...
Next Document:  Ischaemic and pharmacological preconditionings protect liver via adenosine and redox status followin...